AVX-470, an Orally Delivered Anti-Tumour Necrosis Factor Antibody for Treatment of Active Ulcerative Colitis: Results of a First-in-Human Trial

201672 citationsJournal Article

Authors

This trial was registered with Clinicaltrials.gov as study NCT01759056 and with EudraCT as study 2012-004859-27.

Good health and well-being

Published in: Journal of Crohn s and Colitis

Volume 10, Issue 6, pp. 631-640

Field-Weighted Citation Impact: 6.91